This could partly be explained by the fact that HbA1c reflects long-term overall glycemic control and may not accurately capture glucose variability, including postprandial hyperglycemia and hypoglycemia [19]
And those answers will help doctors to prescribe this powerful class of medicines responsibly
Emerging data supports GLP-1s cardiovascular benefits, outweighing risks for most, but shared decision-making is key
The glucagon receptor is particularly dose-sensitive
this was either the final dose or the current dose for people still taking medication
doi:10.1101/cshperspect.a009183 Acknowledgments This work was supported by the Chang Gung Memorial Hospital [Grants CMRPD1A0531, CMRPD1C0231, CMRPG391311, CMRPG3A1131] and the Ministry of Science and Technology, Taiwan [Grant NMRPD181001-3]